APOE and Alzheimer disease: Heterozygous APOE-ε4 carriers (ε2/ε4 or ε3/ε4) have 3-4 times higher risk of developing AD (Honjo et al., 2012[33]; Jagust and Mormino, 2011[35]; Mahley et al., 2006[55]).